Abstract
Metastatic esophageal carcinoma is considered one of the worst prognosis cancersworldwide. The goals of treatment are usually symptoms palliation and possible lifeprolongation. In recent years, the field of immuno-oncology has shown promising treatmentresults and caused a paradigm shift in many types of cancer, as the response is quitelong-lasting. Anti-programmed cell death 1 (anti PD-1) is one of the immuno-oncologydrugs which has been investigated in many types of cancer and currently has beenapproved to be used in melanoma, lung cancer, kidney cancer and bladder cancer. Wereport a case of metastatic esophageal squamous cell carcinoma which had been heavilypretreated but presented an almost complete response to the anti PD-1, pembrolizumab.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
